Intended for healthcare professionals

Letters

Adjuvant trastuzumab for breast cancer: Assessing HER2/neu status incurs more costs for treatment

BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7526.1202 (Published 17 November 2005) Cite this as: BMJ 2005;331:1202
  1. Malcolm R Kell (malcolm.kell@breastcheck.ie), consultant surgeon,
  2. Colm P Power
  1. Mater Misericordiae University Hospital, University College Dublin, Republic of Ireland

    EDITOR—The results of recent trials are likely to continue to fuel the demand for trastuzumab in the adjuvant setting of early breast cancer,1 as well as a possible neoadjuvant treatment in the near future. …

    View Full Text

    Log in

    Log in through your institution

    Subscribe

    * For online subscription